We simply lacked the vaccines to administer. Unlike many of our Western counterparts, we were not stymied by mass mistrust of the medical establishment. African countries excel at running efficient vaccination campaigns, since trial-and-error experience managing tropical diseases means that many governments have highly competent public-health systems. When I received my first jab, most of my neighbors, friends, and colleagues remained exposed to the deadly pandemic.Ĭontrary to popular perception, this is not due to African ineptitude in delivering public health. In the United States, over 75 percent of the population had received at least one dose-in fact, millions of doses had already been thrown away.īut I live in Zambia, where less than one-sixth of the population had received a dose. ![]() As a molecular biochemist who had avidly observed the pandemic response from its earliest days, that felt acutely late. I received my first COVID-19 vaccination on February 9, 2022. Image caption: Bottles on the bottling line of the pharmaceutical plant.Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, Petro Terblanche, managing director of Afrigen Biologics, and Belgian minister for development cooperation Meryame Kitir visit the Afrigen Formulation Facilities, February 11, 2022, in Cape Town, South Africa. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).įollow our news page for the latest updates. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible.īefore the emergence of COVID-19 CEPI’s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. The programmes will leverage rapid response platforms already supported by CEPI as well as new partnerships. CEPI has initiated 9 partnerships to develop vaccines against the novel coronavirus. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. * The COVID-19 Vaccine Global Access Facility is an instrument of the Vaccines pillar of the ACT Accelerator within which CEPI works in partnership with Gavi and the World Health Organisation.ĬEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. , The University of Queensland, The University of Hong Kong, The University of Oxford, a consortium led by Institut Pasteur, and Clover Biopharmaceuticals. To date, CEPI has provided support and funding to develop COVID-19 vaccine candidates to Curevac, Inc., Inovio Pharmaceuticals, Inc., Moderna, Inc., Novavax, Inc. This agreement builds upon CEPI’s initial seed funding for this vaccine candidate which supported the University of Oxford to manufacture clinical trial materials, in addition to funding preclinical studies of AZD1222 at Australia’s Commonwealth Scientific and Industrial Research Organization. Vaccines will be released on a rolling basis as production is completed, and the full quota of 300 million doses is expected to be available by July 2021. If the vaccine is proven to be safe and effective, the first doses to be produced under this agreement are anticipated to be available in early 2021. AstraZeneca will supply the vaccine to the COVID-19 Vaccine Global Access Facility on a no profit basis during the pandemic.ĪZD1222 has now progressed into late-stage Phase II/III clinical trials in more than 10,000 people from across the UK. AstraZeneca and CEPI’s ACT Accelerator partner Gavi have entered into a Memorandum of Understanding which envisages procuring the vaccine produced under the CEPI agreement for distribution by the COVID-19 Vaccine Global Access Facility. It will also purchase manufacturing materials and reserve manufacturing slots, securing a total 300 million doses of vaccine for the COVID-19 Vaccine Global Access Facility.ĬEPI and AstraZeneca are united in their commitment to equitable access to the vaccine. ![]() ![]() ![]() This funding will support the technical transfer of vaccine production technology to manufacturing sites predominantly in Europe, thereby creating additional manufacturing capacity for this vaccine. June 4 2020, Oslo, Norway-CEPI, the Coalition for Epidemic Preparedness Innovations, has today announced a partnership with AstraZeneca (LSE/STO/NYSE:AZN) which will support the manufacture of 300 million doses of the AZD1222 vaccine candidate to be ringfenced for the COVID-19 Vaccine Global Access Facility* if the vaccine is proven to be safe and effective.ĬEPI will invest a total of up to $383m in this partnership.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |